Inbiomotion

Executive Summary

Inbiomotion is a Spanish diagnostics company focused on developing biomarkers to improve the management of breast cancer, the most commonly diagnosed cancer in women worldwide. The company's platform aims to identify patients at high risk of metastatic spread who would benefit from adjuvant therapy, addressing a critical unmet need in personalized oncology. By leveraging advanced molecular profiling, Inbiomotion's tests are designed to guide treatment decisions, potentially reducing overtreatment and improving outcomes. The company was founded in 2010 and is based in Barcelona, operating in the diagnostics category with a private structure. While specific financial details and stage are not disclosed, the company's focus on a high-impact area positions it for strategic partnerships or future funding rounds. Inbiomotion's technology could play a key role in the evolving landscape of precision medicine, where companion diagnostics are increasingly valued. However, the company faces competition from established players and must demonstrate clinical validity and utility to gain market adoption. The company's progress remains closely tied to clinical validation studies and regulatory approvals.

Upcoming Catalysts (preview)

• Q3 2026Publication of key clinical validation study for biomarker test70% success
• Q2 2027Strategic partnership or licensing deal with a diagnostics/life sciences company60% success
• Q4 2026Series B or later-stage funding round55% success